T. Rowe Price (REPL) files 13G/A showing 157,965 shares (0.2%) ownership

Rhea-AI Filing Summary

Replimune Group amended a Schedule 13G/A to report that T. Rowe Price Associates, Inc. beneficially owns 157,965 shares of Replimune common stock, representing 0.2% of the class. The filing states T. Rowe Price has sole voting power over 152,716 shares and sole dispositive power over 157,965 shares. The filer affirms this ownership disclosure while also denying beneficial ownership in a boilerplate statement.

Insights

Institutional Ownership Analyst

Small passive stake reported by T. Rowe Price in Replimune.

The amendment records 157,965 shares (0.2%) of common stock with sole voting and dispositive powers noted. This is a routine ownership disclosure under Schedule 13G/A for an institutional investor.

Stake size and filing type suggest passive investment status; subsequent filings would show any material changes in holdings or voting intent.

Key Figures

Shares beneficially owned: 157,965 shares Percent of class: 0.2% Sole voting power: 152,716 shares +1 more

4 metrics

Shares beneficially owned 157,965 shares Amount beneficially owned reported in Schedule 13G/A

Percent of class 0.2% Percent of common stock reported

Sole voting power 152,716 shares Sole power to vote or direct the vote

Sole dispositive power 157,965 shares Sole power to dispose or direct disposition

Key Terms

Schedule 13G/A, Beneficially owned, Sole dispositive power

3 terms

Schedule 13G/A regulatory

"Amendment No. 8 ) REPLIMUNE GROUP INC COMMON STOCK"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

Beneficially owned regulatory

"Amount beneficially owned: 157965 (b) Percent of class: 0.2 %"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Sole dispositive power regulatory

"(iii) Sole power to dispose or to direct the disposition of: 157965"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 8)

REPLIMUNE GROUP INC

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

76029N106

(CUSIP Number)

04/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 76029N106

1

Names of Reporting Persons

T. Rowe Price Associates, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MARYLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 152,716.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 157,965.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

157,965.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.2 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: REPLIMUNE GROUP INC
(b)	Address of issuer's principal executive offices: 500 UNICORN PARK, WOBURN, MA, 01801
Item 2.
(a)	Name of person filing: T. Rowe Price Associates, Inc.
(b)	Address or principal business office or, if none, residence: 1307 Point Street, Baltimore, MD 21231
(c)	Citizenship: Maryland
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP No.: 76029N106
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 157965
(b)	Percent of class: 0.2 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 152716
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 157965
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

T. Rowe Price Associates, Inc.

Signature:	Ellen York
Name/Title:	Vice President
Date:	05/07/2026

FAQ

What did T. Rowe Price report for REPL in the Schedule 13G/A?

T. Rowe Price reported 157,965 shares of Replimune common stock, equal to 0.2% of the class. The filing lists sole voting power for 152,716 shares and sole dispositive power for 157,965 shares.

Does the Schedule 13G/A indicate T. Rowe Price controls Replimune?

No definitive control is shown; the filing reports voting and dispositive powers for listed shares but does not assert control. It is a disclosure of holdings under Schedule 13G/A, typically used by passive institutional investors.

What is the significance of the 0.2% ownership reported for REPL?

A 0.2% stake is a small institutional holding and is routine to disclose. It does not by itself trigger activist or control presumptions and is below thresholds that normally indicate significant influence.

Who signed the Schedule 13G/A for T. Rowe Price and when?

The filing was signed by Ellen York, Vice President, with a signature date of 05/07/2026 and the cover date showing 04/30/2026 for the reported holdings.

What does the filer mean by denying beneficial ownership in the filing?

The filing includes a boilerplate clause where T. Rowe Price "denies" being the beneficial owner for legal clarity; the Schedule still reports the number of shares for regulatory transparency under beneficial-ownership rules.